TNFRSF1A and metabolic dysfunction-associated steatohepatitis: Atrosimab compared to Atrosab has higher TNFR1 affinity in vitro, lacks any TNFR1 agonistic activity25,26,53and shows similar therapeutic efficacy in different mouse models of acute and chronic inflammation, such as non-alcoholic steatohepatitis (NASH), experimental arthritis and EAE23.